FIELD: medicine.
SUBSTANCE: group of inventions relates to the field of treatment of hyperproliferative disorders, primarily, haematological malignant diseases. Claimed is a combination for treating a hyperproliferative disorder, containing a compound by the formula (I):
or a pharmaceutically acceptable salt thereof and a therapeutic agent selected from tretinoin, cytarabine, pinometostat, vorinostat, ricolinostat, entinostat, decitabine, azacitidine, quizartinib, nutlin-3A, dasatinib, JQ1 and pharmaceutically acceptable salts thereof. Claimed are a pharmaceutical composition and a kit for treating hyperproliferative disorders, containing said combination, as well as a method for treating hematological malignant diseases and an application of the combination for producing a medicinal product.
EFFECT: inventions provide a synergistic therapeutic effect.
30 cl, 22 dwg, 4 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION OF LSD1 INHIBITORS FOR TREATING HAEMATOLOGICAL MALIGNANT DISEASES | 2017 |
|
RU2816659C2 |
| COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | 2016 |
|
RU2759963C2 |
| COMBINATION OF MCL-1 INHIBITOR AND MIDOSTAURIN, ITS APPLICATIONS AND PHARMACEUTICAL COMPOSITIONS | 2019 |
|
RU2818453C2 |
| COMBINATION OF AN MCL-1 INHIBITOR AND A STANDARD DRUG FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES, ITS USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | 2018 |
|
RU2792057C2 |
| PHARMACEUTICAL COMBINATIONS FOR TREATING A MALIGNANT TUMOR | 2017 |
|
RU2726367C2 |
| COMBINATION OF BCL-2 INHIBITOR AND MCL-1 INHIBITOR, USE AND PHARMACEUTICAL COMPOSITIONS THEREOF | 2017 |
|
RU2746705C2 |
| RARA AGONISTS FOR THE TREATMENT OF AML AND MDS | 2017 |
|
RU2799789C2 |
| TREATING MALIGNANT TUMOURS USING MODULATORS OF PI3-KINASE ISOFORMS | 2013 |
|
RU2702908C2 |
| COMBINATION THERAPY | 2017 |
|
RU2754507C2 |
| HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION | 2016 |
|
RU2744897C2 |
